title: Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies.
abstract: OBJECTIVE
  To investigate whether anticyclic citrullinated peptide antibodies (anti-CCP) predict the subset of Japanese patients with Sjögren's syndrome (SS) with articular manifestations.
  
  
  METHODS
  Eighty-seven patients with SS were enrolled. Prevalence of anti-CCP antibodies, IgM rheumatoid factor, anti-Ro/SSA antibody, anti-La/SSB antibody, and serum IgG concentration and their relation to articular manifestations were examined. Articular manifestations included morning stiffness and the presence of tender or swollen joints.
  
  
  RESULTS
  Eighty-seven SS patients were divided into 3 groups: 14 secondary SS with nonerosive rheumatoid arthritis (RA); 47 primary SS with articular manifestations; and 26 primary SS without articular manifestations. Ten out of 14 secondary SS with nonerosive RA expressed anti-CCP. Anti-CCP was the only statistically proven marker preferentially distributed in patients with articular manifestations (the first 2 groups) compared to primary SS without such manifestations; however, its frequency was low in primary SS. No patient with primary SS without articular manifestations expressed anti-CCP.
  
  
  CONCLUSIONS
  Anti-CCP is found in the subset of Japanese with SS with articular manifestations although most of those with anti-CCP-positive SS were classified as secondary SS with RA.
authors.affiliation: Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawakami
authors.forename: Mami
authors.initials: M
authors.lastname: Tamai
authors.forename: Keita
authors.initials: K
authors.lastname: Fujikawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Arima
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Aramaki
authors.forename: Shinya
authors.initials: S
authors.lastname: Kawashiri
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Ichinose
authors.forename: Makoto
authors.initials: M
authors.lastname: Kamachi
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Tomoki
authors.initials: T
authors.lastname: Origuchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ida
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000453:epidemiology / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D011237:Predictive Value of Tests; D012217:Rheumatoid Factor / Q000097:blood; D016036:Seroepidemiologic Studies; D012859:Sjogren's Syndrome / Q000145:classification / Q000453:epidemiology* / Q000276:immunology*
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D007075:Immunoglobulin M; D010456:Peptides, Cyclic; C035356:SS-A antibodies; C035357:SS-B antibodies; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor